Bausch Health–formerly known as Valeant–yesterday reported on a press release that the Journal of Drugs in Dermatology has published results from as many as two Phase III clinical trials, assessing corticosteroid Bryhali (halobetasol propionate) Lotion, 0.01% in patients with psoriasis….
Psoriasis
After announcing it acquired Protein Sciences on July 12, Sanofi informed yesterday about a new cooperation agreement which caused shares to further rise (Wall Street) by 2.7%. The agreement was concluded with Belgium-based Ablynx, a biotech company focused on special…
EMA Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion, recommending a marketing authorization for Almirall’s Skilarence, for the treatment of psoriasis. The product will be available as 30-mg and 120-mg gastro-resistant tablets. Its active ingredient…